Neurogene Completes Dosing in Registrational Trial for Rett Syndrome Gene Therapy NGN-401
NGNE sits 81% above its 52-week low of $14.65.
Summary
Neurogene Inc. announced the successful completion of dosing in its Embolden registrational trial for NGN-401, its lead gene therapy candidate for Rett syndrome, exceeding its enrollment target.
Key Events · Product Development and Regulatory · NGNE
-
Registrational Trial Dosing Completed
Neurogene Inc. has successfully completed dosing in its Embolden registrational trial of NGN-401 for Rett syndrome, enrolling a total of 25 participants, exceeding the initial target of 20 due to strong community demand.
-
Positive Safety Profile Maintained
NGN-401 at the 1E15 vg dose continues to be generally well-tolerated, with no cases of hemophagocytic lymphohistiocytosis (HLH) reported in either the Phase 1/2 or Embolden trials.
-
Key Data Readouts Anticipated
The company expects to present updated interim safety and efficacy data from the Phase 1/2 trial in mid-2026, with topline data from the Embolden registrational trial anticipated in the second half of 2027.
Analysis · NGNE · Life Sciences
Neurogene Inc. has completed dosing in its Embolden registrational trial for NGN-401, a gene therapy for Rett syndrome. This is a critical de-risking milestone, moving the company closer to a potential Biologics License Application (BLA) submission. The trial exceeded its enrollment target due to strong demand, and the therapy continues to show a generally well-tolerated safety profile with no cases of HLH at the 1E15 vg dose. Investors will now focus on the upcoming interim Phase 1/2 data expected mid-2026 and the topline data from the Embolden trial anticipated in the second half of 2027.
At the time of this filing, NGNE was trading at $26.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $418.6M. The 52-week trading range was $14.65 to $37.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.